Facial Plast Surg 2013; 29(05): 365-372
DOI: 10.1055/s-0033-1353376
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Surgical Management of Melanoma

Glen M. Bowen
1   Huntsman Cancer Institute, University of Utah School of Medicine, School of Medicine, Salt Lake City, Utah
› Author Affiliations
Further Information

Publication History

Publication Date:
13 September 2013 (online)

Abstract

Historically, the surgical management for melanoma was ossified for nearly 50 years with the standard of care being wide local excisions with 5-cm margins. Several clinical studies have now brought to light new data that have enabled academic groups such as the American Joint Committee on Cancer and the National Comprehensive Cancer Network to update surgical guidelines reliant on evidence with long-term follow-up. In addition, basic research at the bench has dispelled the myth that all melanomas are genetically identical and behave in a homogeneous way on the basis of the Breslow depth of the original tumor. It is now known that although all melanomas arise from the melanocyte, melanoma encompasses a variety of cancers that are genetically distinct with variable predicted outcomes often associated with the anatomic location of the tumor. This article cites the evidence on which the current surgical guidelines are based and it addresses some of the ongoing controversies regarding the surgical management of the various types of melanoma.

 
  • References

  • 1 Howlader N, Noone AM, Krapcho M , et al, Eds. SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2009_pops09/ , based on November 2011 SEER data submission, posted to the SEER web site, 2012
  • 2 American Cancer Society. Melanoma Skin Cancer Overview. Available at: http://www.cancer.org/Cancer/SkinCancer-Melanoma . Accessed July 2012
  • 3 Bleyer A, O'Leary M, Barr R, Ries LAG , Eds. Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, Including Seer Incidence and Survival: 1975–2000. Bethesda, MD: National Cancer Institute; 2006
  • 4 Handley WS. The pathology of melanotic growths in relation to their operative treatment. Lancet 1907; 1: 927-996
  • 5 Khayat D, Rixe O, Martin G , et al; French Group of Research on Malignant Melanoma. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). Cancer 2003; 97 (8) 1941-1946
  • 6 Ringborg U, Andersson R, Eldh J , et al. Resection margins of 2 versus 5 cm for cutaneous malignant melanoma with a tumor thickness of 0.8 to 2.0.  mm: randomized study by the Swedish Melanoma Study Group. Cancer 1996; 77 (9) 1809-1814
  • 7 Cohn-Cedermark G, Rutqvist LE, Andersson R , et al. Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm. Cancer 2000; 89 (7) 1495-1501
  • 8 Veronesi U, Cascinelli N, Adamus J , et al. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. N Engl J Med 1988; 318 (18) 1159-1162 Erratum in: N Engl J Med 1991 Jul 25;325(4):292
  • 9 Veronesi U, Cascinelli N. Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg 1991; 126 (4) 438-441
  • 10 Cascinelli N. Margin of resection in the management of primary melanoma. Semin Surg Oncol 1998; 14 (4) 272-275
  • 11 Balch CM, Urist MM, Karakousis CP , et al. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg 1993; 218 (3) 262-267 , discussion 267–269
  • 12 Karakousis CP, Balch CM, Urist MM, Ross MM, Smith TJ, Bartolucci AA. Local recurrence in malignant melanoma: long-term results of the multiinstitutional randomized surgical trial. Ann Surg Oncol 1996; 3 (5) 446-452
  • 13 Thomas JM, Newton-Bishop JA, A'Hern R , et al; United Kingdom Melanoma Study Group; British Association of Plastic Surgeons; Scottish Cancer Therapy Network. Excision margins in high-risk malignant melanoma. N Engl J Med 2004; 350 (8) 757-766
  • 14 Guidelines Version NCCN . 3. 2012 Melanoma available at: http://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf . Accessed June 2012
  • 15 Kunishige JH, Brodland DG, Zitelli JA. Surgical margins for melanoma in situ. J Am Acad Dermatol 2012; 66 (3) 438-444
  • 16 National Institutes of Health Consensus Development Conference Statement on Diagnosis and Treatment of Early Melanoma, January 27-29, 1992. Am J Dermatopathol 1993; 15 (1) 34-43 , discussion 46–51
  • 17 Pitman GH, Kopf AW, Bart RS, Casson PR. Treatment of lentigo maligna and lentigo maligna melanoma. J Dermatol Surg Oncol 1979; 5 (9) 727-737
  • 18 Coleman III WP, Davis RS, Reed RJ, Krementz ET. Treatment of lentigo maligna and lentigo maligna melanoma. J Dermatol Surg Oncol 1980; 6 (6) 476-479
  • 19 Tsang RW, Liu FF, Wells W, Payne DG. Lentigo maligna of the head and neck. Results of treatment by radiotherapy. Arch Dermatol 1994; 130 (8) 1008-1012
  • 20 Osborne JE, Hutchinson PE. A follow-up study to investigate the efficacy of initial treatment of lentigo maligna with surgical excision. Br J Plast Surg 2002; 55 (8) 611-615
  • 21 Robinson JK. Margin control for lentigo maligna. J Am Acad Dermatol 1994; 31 (1) 79-85
  • 22 Cohen LM. Management of lentigo maligna and lentigo maligna melanoma with tangential paraffin-embedded sections. J Am Acad Dermatol 1994; 31 (4) 691-692
  • 23 Zitelli JA, Brown CD, Hanusa BH. Surgical margins for excision of primary cutaneous melanoma. J Am Acad Dermatol 1997; 37 (3 Pt 1) 422-429
  • 24 Zalla MJ, Lim KK, Dicaudo DJ, Gagnot MM. Mohs micrographic excision of melanoma using immunostains. Dermatol Surg 2000; 26 (8) 771-784
  • 25 Clayton BD, Leshin B, Hitchcock MG, Marks M, White WL. Utility of rush paraffin-embedded tangential sections in the management of cutaneous neoplasms. Dermatol Surg 2000; 26 (7) 671-678
  • 26 Agarwal-Antal N, Bowen GM, Gerwels JW. Histologic evaluation of lentigo maligna with permanent sections: implications regarding current guidelines. J Am Acad Dermatol 2002; 47 (5) 743-748
  • 27 Albertini JG, Elston DM, Libow LF, Smith SB, Farley MF. Mohs micrographic surgery for melanoma: a case series, a comparative study of immunostains, an informative case report, and a unique mapping technique. Dermatol Surg 2002; 28 (8) 656-665
  • 28 Bienert TN, Trotter MJ, Arlette JP. Treatment of cutaneous melanoma of the face by Mohs micrographic surgery. J Cutan Med Surg 2003; 7 (1) 25-30
  • 29 Huilgol SC, Selva D, Chen C , et al. Surgical margins for lentigo maligna and lentigo maligna melanoma: the technique of mapped serial excision. Arch Dermatol 2004; 140 (9) 1087-1092
  • 30 Hazan C, Dusza SW, Delgado R, Busam KJ, Halpern AC, Nehal KS. Staged excision for lentigo maligna and lentigo maligna melanoma: A retrospective analysis of 117 cases. J Am Acad Dermatol 2008; 58 (1) 142-148
  • 31 Johnson TM, Headington JT, Baker SR, Lowe L. Usefulness of the staged excision for lentigo maligna and lentigo maligna melanoma: the “square” procedure. J Am Acad Dermatol 1997; 37 (5 Pt 1) 758-764
  • 32 Dawn ME, Dawn AG, Miller SJ. Mohs surgery for the treatment of melanoma in situ: a review. Dermatol Surg 2007; 33 (4) 395-402 Review
  • 33 Kelley LC, Starkus L. Immunohistochemical staining of lentigo maligna during Mohs micrographic surgery using MART-1. J Am Acad Dermatol 2002; 46 (1) 78-84
  • 34 El Shabrawi-Caelen L, Kerl H, Cerroni L. Melan-A: not a helpful marker in distinction between melanoma in situ on sun-damaged skin and pigmented actinic keratosis. Am J Dermatopathol 2004; 26 (5) 364-366
  • 35 Geisse JK. Re: Questionable utility of Melan-A/Mart-1 immunoperoxidase staining while doing Mohs surgery for melanoma. Dermatol Surg 2005; 31 (4) 495
  • 36 Bowen AR, Thacker BN, Goldgar DE, Bowen GM. Immunohistochemical staining with Melan-A of uninvolved sun-damaged skin shows features characteristic of lentigo maligna. Dermatol Surg 2011; 37 (5) 657-663
  • 37 Florell SR, Boucher KM, Leachman SA , et al. Histopathologic recognition of involved margins of lentigo maligna excised by staged excision: an interobserver comparison study. Arch Dermatol 2003; 139 (5) 595-604
  • 38 Bub JL, Berg D, Slee A, Odland PB. Management of lentigo maligna and lentigo maligna melanoma with staged excision: a 5-year follow-up. Arch Dermatol 2004; 140 (5) 552-558
  • 39 Testerman TL, Gerster JF, Imbertson LM , et al. Cytokine induction by the immunomodulators imiquimod and S-27609. J Leukoc Biol 1995; 58 (3) 365-372
  • 40 Cotter MA, McKenna JK, Bowen GM. Treatment of lentigo maligna with imiquimod before staged excision. Dermatol Surg 2008; 34 (2) 147-151
  • 41 Ly L, Kelly JW, O'Keefe R , et al. Efficacy of imiquimod cream, 5%, for lentigo maligna after complete excision: a study of 43 patients. Arch Dermatol 2011; 147 (10) 1191-1195
  • 42 Hyde MA, Hadley ML, Tristani-Firouzi P, Goldgar D, Bowen GM. A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions. Arch Dermatol 2012; 148 (5) 592-596
  • 43 Ross MI, Balch CM, Cascinelli N, Edwards MJ. Excision of primary melanoma. In: Balch CM, Houghton AN, Sober AJ, Soon S, , eds. Cutaneous Melanoma, 4th ed. St. Louis, MO: Quality Medical Publishing, Inc.; 2003: 209
  • 44 Lachiewicz AM, Berwick M, Wiggins CL, Thomas NE. Survival differences between patients with scalp or neck melanoma and those with melanoma of other sites in the Surveillance, Epidemiology, and End Results (SEER) program. Arch Dermatol 2008; 144 (4) 515-521
  • 45 Krunic AL, Weitzul S, Taylor RS. Chondrocutaneous advancement flap for reconstruction of helical rim defects in dermatologic surgery. Australas J Dermatol 2006; 47 (4) 296-299
  • 46 Yang D, Yang JF, Morris SF, Tang M, Nie C. Medial plantar artery perforator flap for soft-tissue reconstruction of the heel. Ann Plast Surg 2011; 67 (3) 294-298
  • 47 Bibbo C. Plantar heel reconstruction with a sensate plantar medial artery musculocutaneous pedicled island flap after wide excision of melanoma. J Foot Ankle Surg 2012; 51 (4) 504-508 [Epub 2012 May 19]
  • 48 Wong SL, Morton DL, Thompson JF , et al. Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol 2006; 13 (6) 809-816
  • 49 Andtbacka RH, Gershenwald JE. Role of sentinel lymph node biopsy in patients with thin melanoma. J Natl Compr Canc Netw 2009; 7 (3) 308-317
  • 50 Ferrone CR, Panageas KS, Busam K, Brady MS, Coit DG. Multivariate prognostic model for patients with thick cutaneous melanoma: importance of sentinel lymph node status. Ann Surg Oncol 2002; 9 (7) 637-645
  • 51 Gershenwald JE, Mansfield PF, Lee JE, Ross MI. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (> or = 4 mm) primary melanoma. Ann Surg Oncol 2000; 7 (2) 160-165
  • 52 Gutzmer R, Satzger I, Thoms KM , et al. Sentinel lymph node status is the most important prognostic factor for thick (> or = 4 mm) melanomas. J Dtsch Dermatol Ges 2008; 6 (3) 198-203
  • 53 Morton DL, Thompson JF, Cochran AJ , et al; MSLT Group. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006; 355 (13) 1307-1317 Erratum in: N Engl J Med. 2006 Nov 2;355(18):1944